China Pharma Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2011
Filed with the SEC on Nov 10, 2011 and accepted by EDGAR at Nov 10, 2011, 16:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-07-01 to 2011-09-30 | $21.0m | us-gaap:Revenues |
| Revenue | 9 months2011-01-01 to 2011-09-30 | $58.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2011-07-01 to 2011-09-30 | $13.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2011-01-01 to 2011-09-30 | $37.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2011-07-01 to 2011-09-30 | $7.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2011-01-01 to 2011-09-30 | $21.7m | us-gaap:GrossProfit |
| Operating income | 3 months2011-07-01 to 2011-09-30 | $3.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2011-01-01 to 2011-09-30 | $15.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-07-01 to 2011-09-30 | −$62.4k | us-gaap:InterestExpense |
| Interest expense | 9 months2011-01-01 to 2011-09-30 | −$184.9k | us-gaap:InterestExpense |
| Income tax | 3 months2011-07-01 to 2011-09-30 | −$544.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2011-01-01 to 2011-09-30 | −$2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-07-01 to 2011-09-30 | $3.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months2011-01-01 to 2011-09-30 | $13.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-07-01 to 2011-09-30 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2011-01-01 to 2011-09-30 | $0.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-07-01 to 2011-09-30 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2011-01-01 to 2011-09-30 | $0.31 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2011-01-01 to 2011-09-30 | $5.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2011-01-01 to 2011-09-30 | −$280.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-09-30 | $4.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-09-30 | $106.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-09-30 | $149.1m | us-gaap:Assets |
| Current liabilities | At period end2011-09-30 | $13.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-09-30 | $13.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2011-09-30 | $135.9m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2011-09-30 | 43,529,557 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001010549-11-001255. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.